Internal Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ
Breast Cancer
About this trial
This is an interventional treatment trial for Breast Cancer focused on measuring ductal breast carcinoma in situ, breast cancer in situ
Eligibility Criteria
Inclusion Criteria: Ductal carcinoma in situ (DCIS) confirmed by excisional or needle biopsy Size: < 3 cm on mammogram Unicentric disease Ability to place MammoSite device at time of lumpectomy or within 4 weeks of lumpectomy Patient Age: ≥ 18 years, no upper limit Life expectancy > 5 years Exclusion Criteria: Prior history of cancer other than basal or squamous cell skin cancer or in situ cancer of the cervix Pregnant or breast feeding Multicentric disease Diagnosis of collagen vascular diseases, such as systemic lupus erythematosis, scleroderma, or dermatomyositis
Sites / Locations
- Masonic Cancer Center, University of Minnesota
Arms of the Study
Arm 1
Experimental
Lumpectomy with Brachytherapy
Patients with ductal carcinoma in situ (DCIS, a non-invasive form of breast cancer) treated with standard lumpectomy/brachytherapy following by radiation using the MammoSite (FDA approved a balloon-catheter device placed in the lumpectomy cavity through which high dose radiation is delivered). Tamoxifen may be used postoperatively at the discretion of the treating physicians and patient.